Novo CEO Jorgensen on Biopharma, Insulin Prices, Innovation

Mr. Jorgensen discusses the growth and strategies of the biopharma sector, focusing on organic growth and bolt-ons. He addresses drug pricing trends, particularly in the insulin market, and the potential need for market consolidation. The conversation highlights innovation in diabetes treatment, especially with GLP-1 products, and the company's strong market position. Finally, Mr. Jorgensen explains the corporate strategy and ownership structure that ensures the company's independence and long-term focus on diabetes care.

What strategies are being considered to strengthen the biopharma business?

How has the pricing trend for insulin in the United States changed according to the discussion?

What is the significance of the GLP-1 products mentioned in the text?

What factors contribute to the company's independence in the market?

How does the company plan to continue innovating in the diabetes market?